keyword
MENU ▼
Read by QxMD icon Read
search

Ranibizumab

keyword
https://www.readbyqxmd.com/read/28102456/efficacy-and-safety-of-a-fixed-bimonthly-ranibizumab-treatment-regimen-in-eyes-with-neovascular-age-related-macular-degeneration-results-from-the-rabimo-trial
#1
Nicolas Feltgen, Thomas Bertelmann, Mirko Bretag, Sebastian Pfeiffer, Reinhard Hilgers, Josep Callizo, Lena Goldammer, Sebastian Bemme, Hans Hoerauf
PURPOSE: To evaluate prospectively the efficacy and safety of a fixed bimonthly ranibizumab treatment regimen (RABIMO) in eyes with neovascular age-related macular degeneration (nAMD) and to compare these results with a pro re nata (PRN) treatment scheme. METHODS: This was a 12-month, phase IV, single center, randomised, non-inferiority study. Following three initial monthly injections, patients were randomised to receive either ranibizumab bimonthly (RABIMO group) or ranibizumab PRN (PRN group) (n = 20 each)...
January 19, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/28098725/how-vitreomacular-interface-modifies-the-efficacy-of-anti-vegf-therapy-for-myopic-choroidal-neovascularization
#2
Pierluigi Iacono, Maurizio Battaglia Parodi, Lorenzo Iuliano, Francesco Bandello
PURPOSE: To evaluate the efficacy of intravitreal ranibizumab in the treatment of myopic choroidal neovascularization (mCNV) complicated by vitreoretinal interface alterations. METHODS: Thirty-two patients affected by mCNV and concurrent vitreoretinal interface disorders, including macular epiretinal membrane (18 patients), lamellar macular hole (4 patients), full-thickness macular hole (1 patient), broad/focal vitreomacular traction (3 patients), broad/focal vitreomacular adhesion (4 patients), and myopic foveoschisis (2 patients), were enrolled in a prospective study...
January 16, 2017: Retina
https://www.readbyqxmd.com/read/28096652/erratum-macular-morphology-and-response-to-ranibizumab-treatment-in-patients-with-wet-age-related-macular-degeneration-corrigendum
#3
(no author information available yet)
[This corrects the article on p. 1117 in vol. 10, PMID: 27366051.].
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28089687/stabilizing-effects-for-antibody-formulations-and-safety-profiles-of-cyclodextrin-polypseudorotaxane-hydrogels
#4
Taishi Higashi, Naoko Ohshita, Tatsunori Hirotsu, Yoshihito Yamashita, Keiichi Motoyama, Sawako Koyama, Ruriko Iibuchi, Takayuki Uchida, Shiuhei Mieda, Kenji Handa, Tomoaki Kimoto, Hidetoshi Arima
Antibodies often have poor physicochemical stability during storage and/or transport, which is a serious drawback for the development of antibody-based drugs. In this study, we prepared polypseudorotaxane (PPRX) hydrogels consisting of cyclodextrins (CyDs) and polyethylene glycol (PEG), and evaluated them as stabilizers for commercially available antibody-based drugs. α-CyD and γ-CyD formed PPRX hydrogels with PEG (MW 20,000 Da) in the presence of antibody-based drugs such as omalizumab, palivizumab, panitumumab, and ranibizumab...
January 12, 2017: Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28079756/optical-coherence-tomography-angiography-changes-in-early-type-3-neovascularization-after-anti-vascular-endothelial-growth-factor-treatment
#5
Alexandra Miere, Giuseppe Querques, Oudy Semoun, Francesca Amoroso, Olivia Zambrowski, Thibaut Chapron, Vittorio Capuano, Eric H Souied
PURPOSE: To investigate the morphologic changes on optical coherence tomography angiography (OCTA) of treatment-naive Type 3 neovascularization secondary to exudative age-related macular degeneration after 1 year of anti-vascular endothelial growth factor therapy. METHODS: Consecutive patients diagnosed with treatment-naive early-stage Type 3 neovascularization were enrolled in this retrospective study. All patients underwent color fundus photographs/MultiColor (Heidelberg Engineering) imaging, fluorescein angiography, indocyanine green angiography, structural spectral domain OCT, and OCTA Optovue RTVue XR Avanti (Optovue) at baseline, and repeated OCTA and structural spectral domain OCT at Month 12...
January 10, 2017: Retina
https://www.readbyqxmd.com/read/28079023/incidence-and-growth-of-geographic-atrophy-during-5-years-of-comparison-of-age-related-macular-degeneration-treatments-trials
#6
Juan E Grunwald, Maxwell Pistilli, Ebenezer Daniel, Gui-Shuang Ying, Wei Pan, Glenn J Jaffe, Cynthia A Toth, Stephanie A Hagstrom, Maureen G Maguire, Daniel F Martin
PURPOSE: To estimate the incidence, size, and growth rate of geographic atrophy (GA) during 5 years of follow-up among participants in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). DESIGN: Cohort within a clinical trial. PARTICIPANTS: Participants included in CATT. METHODS: A total of 1185 CATT participants were randomly assigned to ranibizumab or bevacizumab treatment and to 3 treatment regimens...
January 2017: Ophthalmology
https://www.readbyqxmd.com/read/28076566/efficacy-of-aflibercept-on-exudative-age-related-macular-degeneration-in-patients-exhibiting-complete-ranibizumab-resistance-and-tachyphylaxis
#7
Gokcen Gokce, Ali Hakan Durukan, Mehmet Talay Koylu, Murat Kucukevcilioglu
Purpose: The present study compared the efficacy of aflibercept for neovascular age-related macular degeneration (NV-AMD) in patients with complete ranibizumab resistance and tachyphylaxis. Methods: Forty-four eyes of 38 neovascular age-related macular degeneration patients were evaluated. Eyes were divided into a complete resistance group (n=23 eyes) and tachyphylaxis group (n=21 eyes). Results: After three injections, eight (38.1%) patients in the tachyphylaxis group and nine (39...
November 2016: Arquivos Brasileiros de Oftalmologia
https://www.readbyqxmd.com/read/28076563/influence-of-the-epiretinal-membrane-on-ranibizumab-therapy-outcomes-in-patients-with-diabetic-macular-edema
#8
Nimet Yesim Ercalik, Serhat Imamoglu, Esra Turkseven Kumral, Nursal Melda Yenerel, Handan Bardak, Yavuz Bardak
Purpose: To investigate the influence of the epiretinal membrane (ERM) on intravitreal ranibizumab (IVR) therapy for diabetic macular edema (DME). Methods: This retrospective study included 56 eyes of 48 patients with DME divided into two groups: the DME with ERM (study) and only DME (control) groups. Changes in the central macular thickness (CMT) and best-corrected visual acuity (BCVA) were evaluated. Results: In the study group, although the CMT was significantly reduced following the first injection (p<0...
November 2016: Arquivos Brasileiros de Oftalmologia
https://www.readbyqxmd.com/read/28060398/incomplete-retinal-vascularization-after-ranibizumab-treatment-of-retinopathy-of-prematurity
#9
Shelley Day, Annis M Rainey, Clio A Harper
A former 24-week-old premature infant was treated with intravitreal ranibizumab (Lucentis; Genentech, South San Francisco, CA) in one eye and conventional laser in the other eye for aggressive posterior retinopathy of prematurity in both eyes. Fluorescein angiography performed at 149 weeks of age showed persistent avascularity of the temporal peripheral retina in the ranibizumab-treated eye. This case report confirms the need for long-term follow-up of patients treated with ranibizumab monotherapy. [Ophthalmic Surg Lasers Imaging Retina...
January 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28060360/short-term-effects-of-intravitreal-ranibizumab-and-bevacizumab-administration-on-24-h-ambulatory-blood-pressure-monitoring-recordings-in-normotensive-patients-with-age-related-macular-degeneration
#10
A Sengul, R Rasier, C Ciftci, O Artunay, A Kockar, H Bahcecioglu, E Yuzbasioglu
PurposeTo evaluate effects of intravitreal ranibizumab and bevacizumab administration on ambulatory blood pressure monitoring (ABPM) recordings in normotensive patients with age-related macular degeneration (AMD).Patients and methodsA total of 72 patients (mean age: 61.8(6.2) years, 52.8% were females) diagnosed with AMD were included in this study as divided into ranibizumab (n=34) and bevacizumab (n=38) treatment groups. Twenty-four hour, nighttime, and daytime ABMP values for systolic and diastolic BP were recorded in study groups before and after the third intravitreal injection of ranibizumab or bevacizumab...
January 6, 2017: Eye
https://www.readbyqxmd.com/read/28048946/intravitreal-anti-vascular-endothelial-growth-factor-drugs-for-retinal-angiomatous-proliferation-in-real-life-practice
#11
Maurizio Battaglia Parodi, Simone Donati, Francesco Semeraro, Paola Danzi, Ugo Introini, Francesco Viola, Ferdinando Bottoni, Vincenzo Pucci, Andrea Musig, Alfredo Pece, Claudio Azzolini
PURPOSE: To describe the outcomes of intravitreal anti-vascular endothelial growth factor (VEGF) in the treatment of retinal angiomatous proliferation (RAP) in real-life practice in 7 Italian centers under the Progetto Luce initiative. METHODS: Clinical data of 95 eyes of 95 patients affected by RAP, regularly followed up and treated with either intravitreal ranibizumab or bevacizumab over 12 months, were examined. After a loading phase of 3 consecutive injections, retreatments were administered following a pro-re-nata regimen on the basis of the persistence or the recurrence of subretinal/intraretinal fluid on optical coherence tomography, or leakage on fluorescein angiography...
January 3, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28038924/coats-disease-with-macular-oedema-responsive-to-aflibercept-and-argon-laser
#12
M C Guixeres Esteve, A O Pardo Saiz
CLINICAL CASE: A 14 year-old boy with Coats' disease in his right eye, presented with a visual acuity (VA) of 0.1, micro-aneurysms, exudates, a macular oedema of 959 microns, and peripheral telangiectasias. After 12 months follow-up with 6 ranibizumab injections and 3 sessions of argon laser photocoagulation, the macular oedema remained and VA was 0.2. Following 4 aflibercept injections and another 2 laser sessions, he had a good foveal slope and a VA of 0.5, with no recurrences in the last 12 months...
December 27, 2016: Archivos de la Sociedad Española de Oftalmología
https://www.readbyqxmd.com/read/28033280/stereotactic-radiotherapy-in-neovascular-age-related-macular-degeneration-real-life-efficacy-and-morphological-evaluation-of-the-outer-retina-choroid-complex
#13
Mahdy Ranjbar, Maximilian Kurz, Annekatrin Holzhey, Corinna Melchert, Dirk Rades, Salvatore Grisanti
Stereotactic radiotherapy (SRT) is a new approach to treat neovascular age-related macular degeneration (nAMD). The INTREPID trial suggested that SRT could reduce the frequency of regular intravitreal injections (IVIs) with antivascular endothelial growth factor drugs, which are necessary to control disease activity. However, the efficacy of SRT in nAMD and resulting morphological changes have not been validated under real-life circumstances, an issue, which we would like to address in this retrospective analysis...
December 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28033235/factors-influencing-visual-acuity-in-patients-receiving-anti-vascular-endothelial-growth-factor-for-myopic-choroidal-neovascularization
#14
Pierluigi Iacono, Maurizio Battaglia Parodi, Federico Selvi, Maria Cristina Parravano, Adele Chiaravalloti, Monica Varano, Francesco Bandello
PURPOSE: To identify the prognostic variables relative to myopic choroidal neovascularization (CNV) treated with intravitreal ranibizumab/bevacizumab. METHODS: Forty-eight patients with myopic CNV were enrolled in a prospective, interventional, non-randomized 12-month study. Intravitreal ranibizumab/bevacizumab was administered in a pro-re-nata regimen and re-treatment was performed in the presence of angiographic leakage, intraretinal/subretinal fluid on optical coherence tomography, new hemorrhages, five-letter decrease and increased metamorphosia...
December 28, 2016: Retina
https://www.readbyqxmd.com/read/28033234/associations-between-macular-edema-and-circulatory-status-in-eyes-with-retinal-vein-occlusion-an-adaptive-optics-scanning-laser-ophthalmoscopy-study
#15
Yuto Iida, Yuki Muraoka, Akihito Uji, Sotaro Ooto, Tomoaki Murakami, Kiyoshi Suzuma, Akitaka Tsujikawa, Shigeta Arichika, Ayako Takahashi, Yuko Miwa, Nagahisa Yoshimura
PURPOSE: To investigate associations between parafoveal microcirculatory status and foveal pathomorphology in eyes with macular edema (ME) secondary to retinal vein occlusion (RVO). METHODS: Ten consecutive patients (10 eyes) with acute retinal vein occlusion were enrolled, 9 eyes of which received intravitreal ranibizumab (IVR) injections. Foveal morphologic changes were examined via optical coherence tomography (OCT), and parafoveal circulatory status was assessed via adaptive optics scanning laser ophthalmoscopy (AO-SLO)...
December 28, 2016: Retina
https://www.readbyqxmd.com/read/28029445/dual-antagonism-of-pdgf-and-vegf-in-neovascular-age-related-macular-degeneration-a-phase-iib-multicenter-randomized-controlled-trial
#16
Glenn J Jaffe, Thomas A Ciulla, Antonio P Ciardella, Francois Devin, Pravin U Dugel, Chiara M Eandi, Harvey Masonson, Jordi Monés, Joel A Pearlman, Maddalena Quaranta-El Maftouhi, Federico Ricci, Keith Westby, Samir C Patel
PURPOSE: To assess the safety and efficacy of E10030 (Fovista; Ophthotech, New York, NY), a platelet-derived growth factor (PDGF) antagonist, administered in combination with the anti-vascular endothelial growth factor (VEGF) agent ranibizumab (Lucentis; Roche, Basel, Switzerland) compared with ranibizumab monotherapy in patients with neovascular age-related macular degeneration (nAMD). DESIGN: Phase IIb global, multicenter, randomized, prospective, double-masked, controlled superiority trial...
October 28, 2016: Ophthalmology
https://www.readbyqxmd.com/read/28017484/choroidal-haemangioma-and-photodynamic-therapy-anatomical-and-functional-response-of-patients-with-choroidal-hemangioma-treated-with-photodynamic-therapy
#17
O Subirà, H Brosa, D Lorenzo-Parra, L Arias-Barquet, J Català-Mora, E Cobos, P Garcia-Bru, M J Rubio-Caso, J M Caminal-Mitjana
OBJECTIVE: To study the effectiveness and limitations of photodynamic therapy (PDT) as treatment of choice in patients with symptomatic circumscribed choroidal haemangioma. METHODS: A retrospective study was conducted on 16 patients (13 men and 3 women, with mean age of 54.88 years) with circumscribed choroidal haemangioma, who attended our centre and were treated with PDT in the last 7 years. RESULTS: All patients had circumscribed choroidal haemangioma, which caused a decrease in visual acuity (VA) secondary to the presence of intraretinal microcystic oedema or neurosensory detachment...
December 22, 2016: Archivos de la Sociedad Española de Oftalmología
https://www.readbyqxmd.com/read/28006042/evaluating-effects-of-switching-anti-vascular-endothelial-growth-factor-drugs-for-age-related-macular-degeneration-and-diabetic-macular-edema
#18
Frederick L Ferris, Maureen G Maguire, Adam R Glassman, Gui-Shuang Ying, Daniel F Martin
Importance: When a patient with neovascular age-related macular degeneration or diabetic macular edema does not respond to an initial anti-vascular endothelial growth factor agent, usually after several injections, ophthalmologists may switch to another anti-vascular endothelial growth factor agent. Authors of case series have suggested beneficial effects from switching. However, to our knowledge, there are no studies with an appropriate control group to evaluate how such patients would do without switching agents...
December 22, 2016: JAMA Ophthalmology
https://www.readbyqxmd.com/read/28005721/permeability-and-anti-vascular-endothelial-growth-factor-effects-of-bevacizumab-ranibizumab-and-aflibercept-in-polarized-retinal-pigment-epithelial-layer-in-vitro
#19
Naoya Yoshihara, Hiroto Terasaki, Makoto Shirasawa, Hiroki Kawano, Shozo Sonoda, Munekazu Yamaguchi, Teruto Hashiguchi, Toshio Hisatomi, Tatsuro Ishibashi, Taiji Sakamoto
PURPOSE: To determine the effects of bevacizumab, ranibizumab, and aflibercept on the permeability and the effects of anti-vascular endothelial growth factor (VEGF) on highly polarized retinal pigment epithelial cells (RPECs) in vitro. METHODS: Highly polarized RPECs were cultured in the upper chamber of a Transwell system. Anti-VEGF antibodies were added to the upper chamber, and the concentrations of the drugs in the lower chambers were measured. The permeability rates of the three anti-VEGF drugs through the RPEC layer and the concentration of VEGF in each chamber were determined...
January 2017: Retina
https://www.readbyqxmd.com/read/28003780/aflibercept-in-refractory-wet-amd-treated-with-ranibizumab-anatomical-and-visual-outcome
#20
Sleiman Abou-Ltaif
PURPOSE: To assess the anatomical outcome of patients with exudative age-related macular degeneration resistant to ranibizumab treated with aflibercept. METHOD: Prospective, interventional, case series, where we treated a group of patients deemed resistant to Ranibizumab after 6 months of persistence of intra- or subretinal fluid despite continuous treatment. RESULTS: The study included 17 patients, 3 males and 14 females. The average males age was 85 (range 83-87), and that of females was 79...
October 2016: Saudi Journal of Ophthalmology: Official Journal of the Saudi Ophthalmological Society
keyword
keyword
1767
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"